Biogen
BIIB
$126.54
Share price
-0.02%
Change (1 day)
-43.42%
Change (1 year)
Categories
Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
Biogen (BIIB) - Total debt
Total debt on the balance sheet as of March 2025 : $6.62 Billion USD
According to Biogen's latest financial reports the company's total debt is $6.62 Billion USD. A company’s total debt is the sum of all current and non-current debts.
Biogen - Total debt on balance sheet (from 1996 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | $6.63 B | -9.65% |
| 2023-12-31 | $7.33 B | 10.95% |
| 2022-12-31 | $6.61 B | -13.01% |
| 2021-12-31 | $7.60 B | -2.87% |
| 2020-12-31 | $7.82 B | 22.94% |
| 2019-12-31 | $6.36 B | 7.26% |
| 2018-12-31 | $5.93 B | -0.03% |
| 2017-12-31 | $5.93 B | -8.89% |
| 2016-12-31 | $6.51 B | -0.14% |
| 2015-12-31 | $6.52 B | 1018.67% |
| 2014-12-31 | $0.58 B | -2.1% |
| 2013-12-31 | $0.59 B | -47.77% |
| 2012-12-31 | $1.14 B | 7.21% |
| 2011-12-31 | $1.06 B | -11.59% |
| 2010-12-31 | $1.20 B | 9.42% |
| 2009-12-31 | $1.09 B | -1.18% |
| 2008-12-31 | $1.11 B | -28.78% |
| 2007-12-31 | $1.56 B | 1516.42% |
| 2006-12-31 | $96.69 M | 122.57% |
| 2005-12-31 | $43.44 M | -94.89% |
| 2004-12-31 | $0.85 B | -4.17% |
| 2003-12-31 | $0.88 B | 2.43% |
| 2002-12-31 | $0.86 B | 1735.76% |
| 2001-12-31 | $47.18 M | -56.84% |
| 2000-12-31 | $0.10 B | -3.31% |
| 1999-12-31 | $0.11 B | 40.75% |
| 1998-12-31 | $80.32 M | -12.26% |
| 1997-12-31 | $91.55 M | 38.15% |
| 1996-12-31 | $66.27 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | $57.38 B | 766.63% | 🇺🇸 USA |
 Gilead Sciences GILD | $24.95 B | 276.85% | 🇺🇸 USA |
 AbbVie ABBV | $69.88 B | 955.53% | 🇺🇸 USA |
 Pfizer PFE | $61.29 B | 825.68% | 🇺🇸 USA |
 Johnson & Johnson JNJ | $52.25 B | 689.16% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | $0.19 B | -97.04% | 🇺🇸 USA |
 Sanofi SNY | $22.78 B | 244.06% | 🇫🇷 France |
 Bio-Rad Laboratories BIO | $1.36 B | -79.32% | 🇺🇸 USA |
 Illumina ILMN | $2.60 B | -60.63% | 🇺🇸 USA |
 Qiagen QGEN | $1.40 B | -78.73% | 🇳🇱 Netherlands |